243 related articles for article (PubMed ID: 26095609)
1. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
[TBL] [Abstract][Full Text] [Related]
2. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
3. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
4. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC
Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474
[TBL] [Abstract][Full Text] [Related]
5. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
[TBL] [Abstract][Full Text] [Related]
7. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
9. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
11. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
12. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
14. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma.
Ma XL; Jiang M; Zhao Y; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Cao Y; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Ann Surg Oncol; 2018 Jun; 25(6):1686-1694. PubMed ID: 29626309
[TBL] [Abstract][Full Text] [Related]
15. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
16. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
17. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
[TBL] [Abstract][Full Text] [Related]
18. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
19. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
